Eko Aditya Rifai
Eko Aditya Rifai has pursued his bachelor degree of pharmacy and professional degree of pharmacist in University of Indonesia from 2007-2013. He is now a master student of bioinformatics at University of Glasgow, The United Kingdom, starting from 2014. His research interests are in using the computational methods to discover potential inhibitors of enzymes correlated in human diseases, including drug design and molecular dynamics.
Malaria is one of diseases that annually emerge millions victim. Among the other enzymes, plasmepsin is the main enzyme in plasmodium life cycle which degrades hemoglobin during erythrocytic phase in food vacuole. Recently, pharmaceutical industries have been trying to develop therapeutic agents that are able to cure malaria through discovery of new plasmepsin inhibitor compounds. One of developing approaches is in silico method. The chosen in silico screening method in this experiment is structure-based screening by using GOLD software and Indonesian medicinal plants database. Based on the obtained results from this screening, there are 11 inhibitor candidates which are expected to be developed as anti-malarial. These compounds are Trimyristin; Cyanidin 3,5-di-(6-malonylglucoside); Isoscutellarein 4’-methyl ether 8-(6”-n-butylglucuronide); Cyanidin 3-(6”-malonylglucoside)-5-glucoside; Multifloroside; Delphinidin 3-(2-rhamnosyl-6-malonylglucoside); Delphinidin 3-(6-malonylglucoside)-3’,5’-di-(6-p-coumaroylglucoside); Cyanidin 3-[6-(6-sinapylglucosyl)-2-xylosylgalactoside; Kaempferol 3-glucosyl-(1-3)-rhamnosyl-(1-6)-galactoside; Sanggenofuran A and Lycopene with GOLD Score range from 78,4647 to 98,2836. Two of them bind with all residues in catalytic site of plasmepsin which are Asp34 and Asp214.